Tirzepatide vs Epitalon
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Tirzepatide
Tirzepatide is a first-in-class dual GIP/GLP-1 receptor agonist. FDA-approved as Mounjaro (diabetes) and Zepbound (weight loss), it has shown superior weight loss results compared to semaglutide in clinical trials.
Full details →Epitalon
Epitalon (Epithalon) is a synthetic tetrapeptide based on the natural peptide epithalamin, produced by the pineal gland. It is primarily studied for its effects on telomerase activation.
Full details →Side-by-Side Comparison
| Aspect | Tirzepatide | Epitalon |
|---|---|---|
| Mechanism | Activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors, providing synergistic effects on insulin secretion, appetite suppression, and metabolic regulation. The dual mechanism may explain its enhanced efficacy. | Stimulates telomerase production, which can lengthen telomeres on DNA strands. May also regulate melatonin production and circadian rhythms. |
| Typical Dosage | Start at 2.5mg weekly, titrate every 4 weeks through 5mg, 7.5mg, 10mg, 12.5mg, to maximum 15mg weekly. Full titration takes approximately 20 weeks. | Typical protocols: 5-10mg daily for 10-20 days, repeated 2-3 times per year. |
| Administration | Subcutaneous injection once weekly. Rotate injection sites. Slower titration may help reduce GI side effects. | Subcutaneous or intramuscular injection. Usually administered in cycles rather than continuously. |
| Side Effects | Similar to semaglutide: nausea, diarrhea, vomiting, constipation, abdominal pain, decreased appetite. Generally improve with continued use. | Generally well-tolerated. May affect sleep patterns initially. |
| Best For |
Key Differences
Unique to Tirzepatide:
Unique to Epitalon:
Detailed Analysis
Epitalon and Tirzepatide are used for different purposes and have limited overlap in their applications.
Which Should You Choose?
Choose Epitalon for Sleep Quality. Choose Tirzepatide for Fat Loss.